4 New Blood Cancer Trials Readying to Test Immunotherapy Drug
News
AstraZeneca and Celgene Corporation announced they will initiate the FUSION clinical development program of durvalumab (MEDI4736), an investigational human monoclonal antibody against the PDL1 immune checkpoint inhibitor, in hematologic diseases. The FUSION ... Read more